Key statistics dashboard for PTC Therapeutics, Inc. (PTCT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications.
Stock Data
| Price | $67.30 |
| Market Cap | $5.6B |
| Enterprise Value | $5.29B |
| Beta | 0.55 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -138.40 |
| Price / Book | -34.04 |
| P/S | 5.61 |
| EV/EBITDA | 30.47 |
| EV/Sales | 5.24 |
| EV/FCF | -15.90 |
| P/FCF | -17.02 |
| Earnings Yield | -0.68% |
| FCF Yield | -5.90% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 82.14% |
| EBIT Margin | 11.72% |
| EBITDA Margin | 17.20% |
| Operating Margin | 11.52% |
| Net Margin | -3.80% |
| Return on Equity | 21.72% |
| Return on Assets | -1.18% |
| Return on Invested Capital | 2.61% |
| Return on Capital Employed | 4.69% |
Financial Health
| Current Ratio | 3.39 |
| Quick Ratio | 3.28 |
| Cash Ratio | 1.36 |
| Debt / Equity | -4.21 |
| Debt / Assets | 21.43% |
| Net Debt / EBITDA | -2.04 |
| Interest Coverage | 0.63 |
Per-Share Data
| Revenue per share | 12.15 |
| Book Value per share | -1.99 |
| Cash per share | 26.85 |
| FCF per share | -4.01 |
| Tangible Book Value per share | -7.84 |
| Dividend per share | 0.00 |
Related companies: ACLX · ALKS · ARWR · CRNX · KRYS · MTSR · PCVX
Explore sector: Healthcare · Biotechnology
More sections of PTCT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks